NCT05613049 Confounding Factors of Chronic Endometritis in Women With Reproductive Failure
| NCT ID | NCT05613049 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Chinese University of Hong Kong |
| Condition | IVF |
| Study Type | OBSERVATIONAL |
| Enrollment | 720 participants |
| Start Date | 2023-01-26 |
| Primary Completion | 2027-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 720 participants in total. It began in 2023-01-26 with a primary completion date of 2027-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of the study is to investigate the confounding factors of chronic endometritis and therapeutic benefits of antibodies targeting plasma cells in women with reproductive failure.
Eligibility Criteria
Inclusion criteria: 1. Age 20-45 years; 2. Women with a history of 2 or more consecutive miscarriages before 24 weeks of gestation12; or 3. Women who failed to conceive after unprotected intercourse for one year; or 4. Women who failed failure to achieve a clinical pregnancy after two consecutive cycles of IVF, ICSI or frozen embryo replacement cycles where the cumulative number of transferred embryos is no less than four for day-2 embryos and no less than 2 for day-5 embryos (blastocysts), with all embryos being of good quality. Exclusion criteria 1. Uncorrected uterine anomalies, such as the septate or bicornuate uterus, fibroids (submucous/intramural); 2. Untreated hydrosalpinx; 3. History of antiphospholipid syndrome; 4. Known clinical autoimmune disease; 5. Undergoing immunotherapy; 6. Abnormal thyroid function; 7. Abnormal karyotyping. 8. Those with active pelvic inflammatory disease or suspicion of infection etc.
Contact & Investigator
Jacqueline Pui Wah Chung, MBBS
PRINCIPAL INVESTIGATOR
Chinese University of Hong Kong
Frequently Asked Questions
Who can join the NCT05613049 clinical trial?
This trial is open to female participants only, aged 20 Years or older, up to 45 Years, studying IVF. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05613049 currently recruiting?
Yes, NCT05613049 is actively recruiting participants. Contact the research team at staceywong@cuhk.edu.hk for enrollment information.
Where is the NCT05613049 trial being conducted?
This trial is being conducted at Hong Kong, Hong Kong.
Who is sponsoring the NCT05613049 clinical trial?
NCT05613049 is sponsored by Chinese University of Hong Kong. The principal investigator is Jacqueline Pui Wah Chung, MBBS at Chinese University of Hong Kong. The trial plans to enroll 720 participants.